Physician profile
Aymen Atallah
NPI 1417902339
$11,947.52
in general payments reported to CMS, 2019-2025
52 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,406 · 2020: $2,116 · 2021: $1,795 · 2022: $1,424 · 2023: $1,602 · 2024: $1,950 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,161 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.09 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,838.43 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,402.64 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,095.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $898.47 | 2019-2025 | |
| Lilly USA, LLC | $656.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $589.50 | 2019-2024 | Xarelto |
| Neurocrine Biosciences, INC. | $442.98 | 2021-2025 | Ingrezza, Ongentys |
| Amarin Pharma, INC. | $402.44 | 2019-2022 | |
| Abbott Laboratories | $389.55 | 2021-2025 | Freestyle Libre 3, Mitraclip, Freestyle Libre 2 |
| Exact Sciences Corporation | $346.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $327.33 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $272.46 | 2019-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $248.26 | 2019-2025 | Watchman Flx |
| Lundbeck LLC | $239.31 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $218.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aymen Atallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.